Purple Biotech (PPBT) CFO details multi-million share options and RSUs

Rhea-AI Filing Summary

PURPLE BIOTECH LTD. Chief Financial Officer Shai S. Lankry has updated his reported equity holdings. The filing shows stock options to purchase 3,000,000 ordinary shares under one grant and 3,550,000 ordinary shares under another, all under the company’s 2016 Equity-Based Incentive Plan.

The options for 3,000,000 ordinary shares carry an exercise price of $0.01359375 per share and expire on April 29, 2030. The options for 3,550,000 ordinary shares have an exercise price of $0.00309375 per share and expire on October 21, 2030, with 295,833 shares already vested.

The holdings also include 3,254,167 unvested restricted stock units, each representing one ordinary share subject to time-based vesting and settled in ordinary shares. The ordinary shares may be represented by American Depositary Shares, with each ADS currently representing 2,000 ordinary shares.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Lankry Shai S

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 3,000,000 shares (Direct); Ordinary Shares — 3,550,000 shares (Direct)

Footnotes (1)

1. Includes 3,254,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares Represents stock option to purchase 3,000,000 Ordinary Shares (equivalent to 1,500 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The options to purchase 1,000,000 Ordinary Shares will vest on April 29, 2026, with the remaining 2,000,000 Ordinary Shares vesting in equal quarterly installments until April 29, 2028. The exercise price of this stock option is $0.01359375 per Ordinary Share and the option expires on April 29, 2030. Represents stock option to purchase 3,550,000 Ordinary Shares (equivalent to 1,775 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 295,833 Ordinary Shares are vested and exercisable, with the remaining options to purchase 3,254,167 Ordinary Shares vesting in equal quarterly installments until October 21, 2028. The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030

Key Figures

Option grant size 1: 3,000,000 ordinary shares Exercise price grant 1: $0.01359375 per ordinary share Option grant size 2: 3,550,000 ordinary shares +4 more

7 metrics

Option grant size 1 3,000,000 ordinary shares Stock option under 2016 Equity-Based Incentive Plan

Exercise price grant 1 $0.01359375 per ordinary share Option expiring April 29, 2030

Option grant size 2 3,550,000 ordinary shares Second stock option under 2016 Equity-Based Incentive Plan

Exercise price grant 2 $0.00309375 per ordinary share Option expiring October 21, 2030

Vested portion grant 2 295,833 ordinary shares Already vested and exercisable from 3,550,000-share option

Unvested RSUs 3,254,167 units Each RSU represents one ordinary share, time-based vesting

ADS ratio 1 ADS = 2,000 ordinary shares Ordinary shares may be represented by American Depositary Shares

Key Terms

restricted stock units ("RSUs"), American Depositary Shares, 2016 Equity-Based Incentive Plan

3 terms

restricted stock units ("RSUs") financial

"Includes 3,254,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

2016 Equity-Based Incentive Plan financial

"issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan"

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lankry Shai S

(Last) (First) (Middle)

4 OPPENHEIMER STREET

SCIENCE PARK

(Street)

REHOVOT 7670104

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
PURPLE BIOTECH LTD. [ PPBT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)
03/27/2026

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	3,550,000(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	(2)	Ordinary Shares	3,000,000	(2)	D
Stock Option (Right to Buy)	(3)	(3)	Ordinary Shares	3,550,000	(3)	D

Explanation of Responses:

1. Includes 3,254,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares

2. Represents stock option to purchase 3,000,000 Ordinary Shares (equivalent to 1,500 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The options to purchase 1,000,000 Ordinary Shares will vest on April 29, 2026, with the remaining 2,000,000 Ordinary Shares vesting in equal quarterly installments until April 29, 2028. The exercise price of this stock option is $0.01359375 per Ordinary Share and the option expires on April 29, 2030.

3. Represents stock option to purchase 3,550,000 Ordinary Shares (equivalent to 1,775 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 295,833 Ordinary Shares are vested and exercisable, with the remaining options to purchase 3,254,167 Ordinary Shares vesting in equal quarterly installments until October 21, 2028. The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030

	/s/ Shai Lankry	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider ownership did Purple Biotech (PPBT) CFO report on this Form 3/A?

The CFO reported holdings that include stock options over millions of ordinary shares and several million unvested RSUs. These positions reflect equity-based compensation under Purple Biotech’s 2016 Equity-Based Incentive Plan, rather than new open‑market purchases or sales.

How many stock options does the Purple Biotech (PPBT) CFO hold and at what prices?

He holds options to purchase 3,000,000 ordinary shares at $0.01359375 per share and 3,550,000 ordinary shares at $0.00309375 per share. Both option grants were issued under the 2016 Equity-Based Incentive Plan and have expiration dates in 2030.

What are the vesting terms of the Purple Biotech (PPBT) CFO’s 3,000,000-share option grant?

For the 3,000,000-share option, 1,000,000 ordinary shares will vest on April 29, 2026. The remaining 2,000,000 shares will then vest in equal quarterly installments until April 29, 2028, subject to the plan’s time‑based vesting conditions.

What are the vesting terms of the 3,550,000-share option held by the Purple Biotech (PPBT) CFO?

For the 3,550,000-share option, 295,833 ordinary shares are already vested and exercisable. The remaining 3,254,167 ordinary shares will vest in equal quarterly installments until October 21, 2028, providing a staggered vesting schedule over multiple years.

How many unvested RSUs does the Purple Biotech (PPBT) CFO hold?

He holds 3,254,167 unvested restricted stock units, each tied to one ordinary share of Purple Biotech. These RSUs are subject to time-based vesting conditions and will be settled in ordinary shares as they vest over the specified schedule.

How do Purple Biotech (PPBT) American Depositary Shares relate to ordinary shares?

Each Purple Biotech American Depositary Share currently represents 2,000 ordinary shares. This means option and RSU amounts stated in ordinary shares can be translated into ADS terms by applying this 2,000‑to‑1 ratio, if investors follow the ADS instead of ordinary shares.